Monte Rosa Therapeutics (GLUE) AI Stock Analysis

• Market Cap: $302.63M
• Dividend Yield: N/A
• Average Volume (3M): 427.91K
• Price to Earnings (P/E): 73.1
• Beta (1Y): 2.04
• Revenue Growth: N/A
• EPS Growth: 61.09%
• Country: US
• Employees: 142
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): 0.57
• Shares Outstanding: 61,509,823
• 10 Day Avg. Volume: 456,888
• 30 Day Avg. Volume: 427,913
• PEG Ratio: -0.08
• Price to Book (P/B): 1.32
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.41
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 1.29
• Enterprise Value/Gross Profit: 2.26
• Enterprise Value/Ebitda: -1.10
• 1Y Price Target: $14.75
• Price Target Upside: 200.41% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 52 Neutral
• Price Target: ―

Monte Rosa Therapeutics exhibits strengths in clinical progress and a robust financial runway, counterbalanced by ongoing profitability issues and bearish technical indications. While clinical advancements and strategic partnerships offer growth potential, the negative P/E ratio and reliance on external funding present risks.

Positive Factors

Clinical Trials

Monte Rosa plans to expand enrollment of their CRPC cohort to n=20-30 patients if a positive efficacy signal continues to be observed.

Financial Performance

GLUE reported Q1 net income of $47MM and cash of $331MM (runway into 2028).

Partnerships

Monte Rosa's lead I&I asset, MRT-6160, is advancing toward multiple Phase 2 trials, supported through a partnership with Novartis.

Negative Factors

Limited Upside

The upside is limited in 2025 given MRT-6160 is now partnered and the MRT-2359 Ph1 update may have too few patients to fully interpret its profile.

Market Sentiment

Short Interest is 17.5% of the float.

Uncertainty in Forecasting

It's currently challenging to forecast the precise development paths and subsequent potential revenues for the assets.

Monte Rosa Therapeutics Business Overview & Revenue Model

Company Description

Monte Rosa Therapeutics is a biotechnology company focused on the discovery and development of novel small molecules that harness the body's natural mechanisms to selectively degrade disease-causing proteins. The company operates within the pharmaceutical and biotechnology sectors, with a primary emphasis on advancing therapies for cancer and other serious diseases through its proprietary drug discovery platform.

How the Company Makes Money

Monte Rosa Therapeutics generates revenue primarily through the development and commercialization of its proprietary small molecule degraders. The company may enter into licensing agreements, collaborations, or partnerships with larger pharmaceutical companies to co-develop and commercialize its drug candidates. Revenue can be obtained from upfront payments, milestone payments based on the achievement of specific clinical or regulatory milestones, and royalties from product sales once the therapies are commercialized. Additionally, Monte Rosa may benefit from research grants or funding from private or public institutions to support its R&D activities.

Monte Rosa Therapeutics Financial Statement Overview

Summary

Monte Rosa Therapeutics shows improvement in cash flow and revenue introduction, yet struggles with profitability, relying heavily on financing activities. A stable balance sheet provides some financial protection.

Income Statement

Monte Rosa Therapeutics experienced positive revenue generation in the latest year with a gross profit margin of 100% as revenue equaled gross profit. However, the company continues to face challenges with negative EBIT and net income, affecting its profitability. Despite the introduction of revenue, the net profit margin remains negative, indicating ongoing financial challenges.

Balance Sheet

The company's debt-to-equity ratio is moderate, reflecting a balanced approach to leveraging debt. However, the return on equity remains negative due to persistent net losses. A significant portion of the company's assets is funded by equity, as indicated by a stable equity ratio, which provides a buffer against financial risks.

Cash Flow

Monte Rosa Therapeutics has shown improvement in operating cash flow, turning positive from negative in the previous year. There is a noticeable improvement in free cash flow, indicating better cash management. However, cash flow from operations is still reliant on financing activities, reflecting dependency on external funding.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
159.49M	75.62M	0.00	0.00	0.00	0.00
	Gross Profit
155.37M	67.50M	-6.22M	-8.56M	-2.13M	-537.00K
	EBIT
-2.13M	-81.11M	-143.31M	-112.38M	-72.88M	-28.01M
	EBITDA
6.14M	-72.99M	-137.09M	-99.94M	-70.75M	-27.47M
	Net Income Common Stockholders
6.15M	-72.70M	-135.35M	-104.62M	-71.94M	-36.07M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
326.07M	372.15M	232.41M	262.83M	346.07M	41.70M
	Total Assets
393.20M	438.73M	303.75M	342.39M	366.33M	49.38M
	Total Debt
41.86M	42.72M	46.04M	47.00M	0.00	67.76M
	Net Debt
-36.67M	-181.54M	-82.06M	-7.91M	-346.07M	26.07M
	Total Liabilities
118.04M	215.80M	124.50M	70.98M	18.81M	98.11M
	Stockholders Equity
275.16M	222.94M	179.25M	271.41M	347.51M	-48.73M
Cash Flow		Free Cash Flow
30.48M	38.01M	-62.84M	-105.38M	-69.09M	-26.44M
	Operating Cash Flow
34.67M	42.00M	-43.80M	-92.47M	-59.36M	-23.05M
	Investing Cash Flow
-154.53M	-44.45M	88.80M	-219.22M	-9.65M	-3.39M
	Financing Cash Flow
98.66M	98.89M	27.49M	20.47M	377.56M	60.06M

Monte Rosa Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.91
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GLUE, the sentiment is Positive. The current price of 4.91 is above the 20-day moving average (MA) of 4.45, above the 50-day MA of 4.43, and below the 200-day MA of 6.10, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 59.39 is Neutral, neither overbought nor oversold. The STOCH value of 72.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GLUE.

Monte Rosa Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARCT	56 Neutral	$342.80M	―	-27.40%	―	15.40%	35.42%
TSHA	54 Neutral	$698.29M	―	-159.34%	―	-48.97%	69.32%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
GLUE	52 Neutral	$302.63M	73.07	2.88%	―	―	61.09%
SEPN	50 Neutral	$463.85M	―	3.77%	―	―	―
OLMA	46 Neutral	$277.79M	―	-41.59%	―	―	0.42%
AURA	43 Neutral	$413.57M	―	-56.24%	―	―	9.22%

Monte Rosa Therapeutics Corporate Events

Monte Rosa Therapeutics Reports Q4 2024 Financial Results

Monte Rosa Therapeutics announced its fourth quarter 2024 financial results and provided updates on its clinical programs. The Phase 1 study of MRT-6160 showed promising results in VAV1 degradation and cytokine inhibition, supporting its potential in immune-mediated diseases and paving the way for Phase 2 studies. Meanwhile, the Phase 1/2 study of MRT-2359 demonstrated encouraging clinical responses in castration-resistant prostate cancer, prompting the company to focus on this cohort while deprioritizing other tumor types. Monte Rosa’s strong cash position is expected to fund operations into 2028, and the company continues to advance its early-stage pipeline, including the NEK7-directed MRT-8102 and other molecular glue degrader programs.